Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.71 |
| ▸ | RAB9A | P51151 | 6/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | CNR2 | P34972 | 5/20 | 0.71 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | STAT1 | P42224 | 1/20 | 0.55 |
| ▸ | NAMPT | P43490 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | FAAH | O00519 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | CCR2 | P41597 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10253740 | 0.89 | CNR2 (0.69) | NPC1RAB9AKMT2ACNR2MAPT | |
| SCHEMBL10253212 | 0.87 | CNR2 (0.70) | NPC1RAB9AKMT2ACNR2MAPT | |
| SCHEMBL10253825 | 0.84 | CNR2 (0.72) | NPC1RAB9AKMT2ACNR2SMN1; SMN2 | |
| SCHEMBL10253249 | 0.83 | CNR2 (0.78) | NPC1RAB9AKMT2ACNR2MAPT | |
| SCHEMBL10253053 | 0.83 | CNR2 (0.71) | NPC1RAB9AKMT2ACNR2MAPT | |
| SCHEMBL10253343 | 0.83 | CNR2 (1.00) | CNR2MAPTNAMPTALDH1A1PTPN1 | |
| SCHEMBL8361622 | 0.83 | RAB9A (0.97) | NPC1RAB9AKMT2ACNR2MAPT | |
| SCHEMBL10253397 | 0.82 | CNR2 (0.79) | NPC1RAB9AKMT2ACNR2MAPT | |
| SCHEMBL10253368 | 0.81 | CNR2 (1.00) | CNR2MAPTNAMPTALDH1A1KCNH2 | |
| SCHEMBL10253447 | 0.81 | CNR2 (0.78) | CNR2MAPTNAMPTPTPN1CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173638-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-08 | — | — | US | disclosed |
| US-8173638-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-08 | — | — | US | disclosed |
| US-20100009964-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-14 | — | — | US | disclosed |
| US-20100009964-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-14 | — | — | US | disclosed |
| WO-2008064054-A2 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009964-A1 | Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | NPC1 1425/4885RAB9A 2182/4885KMT2A 3896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.